Watch original video:

Nasdaq warned biotechnology company MDRNA that it doesn’t meet the minimum $10 million stock value requisition to subsist listed on the market, the resolute said Monday.

The Bothell partnership, formerly known as Nastech Pharmaceutical, aforesaid it would provide Nasdaq by Dec. 3 with its strategy on for what reason to meet listing requirements.

“We are confident that Nasdaq will find our plan acceptable,” said MDRNA Chief Executive Michael French in a statement.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com

Original text: {news-link}